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Abstract 1 
 2 
Vascular smooth muscle cells (VSMCs) are a major cell type present at all stages in 3 
atherosclerotic plaques.  According to the ‘response to injury’ and ‘vulnerable plaque’ 4 
hypotheses, contractile VSMCs recruited from the media undergo phenotypic conversion to 5 
proliferative synthetic cells that elaborate extracellular matrix to form the fibrous cap and 6 
hence stabilise plaques.  However, recent lineage tracing studies have highlighted flaws in the 7 
interpretation of former studies, revealing these to have underestimated both the content and 8 
functions of VSMCs in plaques, and have thus challenged our view on the role of VSMCs in 9 
atherosclerosis.  It is now evident that VSMCs are even more plastic than previously 10 
recognised, and can adopt alternative phenotypes including cells resembling foam cells, 11 
macrophages, mesenchymal stem cells, and osteochondrogenic cells, which could contribute 12 
both positively and negatively to disease progression.  In this review, we present the evidence 13 
for VSMC plasticity and summarise the roles of VSMCs and VSMC-derived cells in 14 
atherosclerotic plaque development and progression.  Correct attribution and spatio-temporal 15 
resolution of clinically beneficial and detrimental processes will underpin the success of any 16 
therapeutic intervention aimed at VSMCs and their derivatives. 17 
 18 
 19 
Introduction  20 
 21 
Atherosclerosis is the formation of plaques containing lipid, cells, debris and scar tissue in 22 
the intima of arteries.  As the main pathological process underlying myocardial infarction, 23 
angina, heart failure and stroke, atherosclerosis has been the leading cause of morbidity and 24 
mortality in the Western world for over half a century and is now the top cause of death 25 
globally1.  A significant role for vascular smooth muscle cells (VSMCs) in atherosclerosis 26 
was established in the 1960s - as soon as electron microscopy made it possible to identify 27 
smooth muscle-like cells in the media of normal arteries2, and it was ascertained that the 28 
majority of cells in atherosclerotic plaques had characteristics of VSMCs but with altered 29 
phenotypes3–5.  However, the perception of how VSMCs contribute to plaque development, 30 
remodelling and stabilisation has changed substantially over the last half-century (Box 1), 31 
and recent studies have questioned long-standing assumptions about the identity of cells in 32 
plaques, demanding a re-evaluation of the role of VSMCs in atherosclerosis. 33 
 34 
 35 
Identification of VSMCs  36 
 37 
VSMCs are defined based upon anatomical localisation (i.e. within the vasculature) and 38 
functionality; in healthy arteries VSMCs are located in the medial layer where they are 39 
responsible for arterial contraction and production of extracellular matrix (ECM), and play 40 
important roles in compliance and elastic recoil in response to changing haemodynamic 41 
conditions.  VSMC functions are key determinants of the properties of vessels throughout the 42 
arterial tree; VSMC-derived elastin is crucial for elastic recoil in large elastic arteries (such as 43 
the aorta), whilst VSMC contraction is largely responsible for modulating arterial diameter in 44 
muscular arteries and arterioles (the latter being of great importance to systemic arterial 45 
resistance).  Functionality is usually inferred from a combination of characteristics, including 46 
morphology and expression of ‘VSMC-specific’ function-associated markers (which are 47 
typically proteins and glycosaminoglycans).  In healthy arteries, VSMCs are fusiform-shaped 48 
cells that express contractile proteins (including smooth muscle alpha actin (αSMA) and 49 
smooth muscle myosin heavy chain (SMMHC) which are organised into myofilaments) and 50 
 3 
secrete ECM macromolecules (including elastins, collagens and proteoglycans).  Most 1 
studies to date have relied on these markers6–9 or gene expression profiles10 for identification 2 
of VSMCs.  However, as a necessary corollary of their role in tissue homeostasis and repair, 3 
VSMCs exhibit considerable phenotypic plasticity in atherosclerosis, in response to injury, 4 
and upon culture in vitro, which is often accompanied by marked changes in cell morphology 5 
and expression of ‘VSMC-specific’ markers.  Hence, definition of cell-type based on 6 
functionality or ‘specific’ markers as a proxy for cell identification is problematic, and has 7 
confounded studies on the true extent of the role of VSMCs in atherosclerosis11.  8 
  9 
Developments in genetic engineering have enabled specific labelling of VSMCs in mice, 10 
making fate mapping and lineage tracing of VSMCs possible.  For example, inducible VSMC 11 
labelling systems (such as a tamoxifen inducible-recombinase driven by ‘VSMC-specific’ 12 
gene promoters (typically MYH1112 or TAGLN13–15)16 combined with reporter proteins17,18), 13 
result in specific and stable labelling of VSMCs at baseline and enable unambiguous tracing 14 
of VSMCs and VSMC-derived cells during atherogenesis, even when VSMC characteristics 15 
may otherwise be lost or gained11,17–24.  This elegant approach has led to important advances 16 
in our understanding of the functional consequences of developmental origin, plasticity, 17 
clonality and ultimately the fate of VSMCs in plaques, providing evidence for a more 18 
complex and prominent role for VSMCs and VSMC-derived cells in atherosclerosis. 19 
 20 
 21 
Origin of VSMCs 22 
 23 
VSMCs are derived from multiple distinct progenitors in embryogenesis (detailed in Box 2), 24 
with little or no mixing between different lineages25–27,  resulting in anatomical segmentation 25 
across the arterial tree.  Furthermore, there is evidence for positional identity among VSMCs 26 
along the anterior-posterior, dorso-ventral, and right-left axes of the embryo28–30.  Embryonic 27 
lineage can have important functional consequences; for example, VSMCs show lineage-28 
dependent responses to important signalling pathways such as TGF-β31,32, PDGF33, 29 
MRTFB34,35, NF-κB36 and angiotensin II37.  These findings exemplify a fundamental 30 
limitation in defining VSMCs on the basis of ‘VSMC-specific’ function-associated markers, 31 
which may be similarly expressed in all VSMC lineages (potentially evoked through different 32 
pathways that converge on the same set of ‘VSMC-specific’ genes, as detailed in Box 3), 33 
whilst different VSMC lineages may have distinct functional characteristics.  34 
 35 
Lineage tracing studies have unambiguously demonstrated that VSMCs contribute 36 
substantially to plaque formation in murine models of atherosclerosis, generating 30-70% of 37 
all plaque cells11,18–20,22,23.  In particular, most αSMA positive cells within the fibrous cap are 38 
VSMC lineage label positive, refuting earlier ideas38,39 that bone marrow-derived cells 39 
generate αSMA positive cells40–42.  VSMC-derived cells that express mesenchymal stem cell 40 
markers (in particular Sca1) have also been identified in the healthy media43 and in 41 
plaques11,43, and may represent a plastic intermediate population that is readily responsive to 42 
inflammation and capable of generating contractile or phenotypically switched VSMCs43.  43 
However, these studies do not rule out a contribution from other sources of progenitors to 44 
plaque VSMCs (Box 2).  45 
 46 
Evidence for clonality (discussed below) of VSMCs and VSMC-derived cells in plaques 47 
indicates that the majority of plaque cells derive from recruitment and proliferation of local 48 
VSMCs, while the anatomical distribution of different developmental origins of VSMCs (and 49 
perhaps other cell types, such as pericytes and endothelial cells) may contribute to the 50 
 4 
anatomical distribution of atherosclerosis susceptibility44.  This idea is supported by the 1 
finding that segments of aorta from atherosclerosis-prone and -resistant regions maintain their 2 
atherosclerosis susceptibility upon transplantation to alternative sites45.  Definitive evidence 3 
of similar anatomical segmentation of VSMCs populations in humans is currently lacking, 4 
but supported in part by studies showing that human arteries are composed of clonal patches 5 
of VSMCs46–48.  Furthermore, advances in understanding development of different VSMC 6 
lineages in vivo have led to generation of VSMCs from stem cells49, which will facilitate 7 
better disease modelling in human cells in vitro50. 8 
 9 
 10 
Plasticity of VSMCs 11 
 12 
VSMCs display a fully functional, differentiated phenotype in healthy vessels, yet retain 13 
remarkable plasticity.  De-differentiation, modulation, or phenotypic switching of VSMCs is 14 
characterised by reduced myofilament density and lower expression of contractile proteins.  15 
De-differentiated VSMCs upregulate expression of ECM components and ECM-remodelling 16 
enzymes, have increased levels of secretory organelles, and express pro-inflammatory 17 
cytokines51.  Consequently, phenotypically-switched VSMCs are often referred to as 18 
‘synthetic’, whilst VSMCs expressing high levels of contractile proteins are generally 19 
described as ‘contractile’ (although these definitions imply explicit functional changes that 20 
are usually only inferred and very rarely quantified).  Activation of VSMC proliferation and 21 
migration has also been associated with the synthetic, de-differentiated state, but coordinated 22 
regulation of these processes has not been documented and mitotic VSMCs with high levels 23 
of contractile proteins have been observed52,53.  24 
 25 
Phenotypic switching is a reversible process, at least in the early stages. For example, a 26 
general, transient loss of contractile protein expression is observed after vascular injury, 27 
followed by reestablishment of the contractile phenotype after vessel repair54. VSMCs 28 
displaying phenotypes ranging from contractile to synthetic states have also been observed 29 
both in vivo53 and in VSMC cultures in vitro55,58, illustrating that phenotypic switching is not 30 
a binary process.  VSMC heterogeneity in morphology and gene expression43,56 is also seen 31 
in healthy vessels, including detection of rare atypical VSMCs marked by Sca1/Ly6a, that 32 
express phenotypic switch-associated genes43.  At the molecular level, VSMC phenotype is 33 
governed by regulatory transcription factors (including myocardin/SRF57 and KLF411), which 34 
integrate input from the environment (including growth factors, cytokines, lipid mediators, 35 
contact with the ECM and other cells) and is regulated at multiple levels, including epigenetic 36 
mechanisms (summarised in Box 3). 37 
 38 
Lineage tracing studies have revealed that VSMCs exhibit greater than anticipated plasticity 39 
in atherosclerosis (Table 1).  Within plaques a large proportion of reporter-expressing 40 
VSMC-derived cells do not have detectable levels of the contractile smooth muscle cell 41 
marker αSMA11,20.  Instead, some plaque reporter-expressing cells were positive for Mac-320, 42 
Lgals311and CD6817 - markers that have been previously used to study macrophages in 43 
atherosclerosis.  Stimulation of VSMCs in vitro with cholesterol similarly induces expression 44 
of macrophage-associated genes58,59 and promotes a phagocytic phenotype11.  Human 45 
VSMC-derived plaque cells were also found to express CD6811, consistent with previous 46 
studies co-detecting CD68 and αSMA in human plaque cells60,61.  These results support the 47 
hypothesis proposed by Wissler in 196862 that at least a subset of foam cells are VSMC-48 
derived.  This should be considered when interpreting studies on macrophage function, which 49 
rely only on marker expression.  Similarly, VSMCs have been proposed to generate 50 
 5 
osteochondrogenic and mesenchymal stem cell-like plaque cells based on expression of 1 
mineralising ECM proteins63,64 and Sca1/Eng11 respectively.  Expanded plasticity of VSMCs 2 
in atherosclerosis was confirmed by transcriptional profiling of individual VSMC-lineage 3 
plaque cells, revealing subpopulations of cells expressing Ly6a/Sca1, CD68 and 4 
Sox9/Chad43.  5 
 6 
 7 
Clonality of VSMCs  8 
 9 
The combination of multi-colour recombination markers (such as the confetti or rainbow 10 
system18,22) with genetic lineage tracing of VSMCs has demonstrated that, surprisingly, 11 
mouse VSMC-derived plaque cells are generated by clonal expansion of relatively few cells 12 
within the vessel wall17,20,22,23.  In contrast, most medial cells do not contribute to mouse 13 
plaque formation and the role of VSMC migration independent of proliferation is limited20.  14 
Indeed, phenotypically distinct VSMC-derived plaque cells are generated from a common 15 
‘ancestor’.  Observations of plaques at different timepoints suggest that, in mice, VSMCs 16 
first generate the cap followed by adoption of switched phenotypes in the lesion core23, but 17 
this remains to be experimentally tested.   18 
 19 
The molecular mechanisms underlying clonality are yet to be established, but macrophage 20 
secreted factors have been implicated.  For example, bone-marrow transplantation from 21 
integrin β3-deficient mice into ApoE null mice results in polyclonal plaque VSMCs and 22 
VSMC-derived cells23, whilst conditioned media from integrin β3-deficient macrophages is 23 
more mitogenic to VSMCs than conditioned media from wild-type macrophages23.  Early 24 
stage cap VSMCs are highly proliferative and express αSMA, SMMHC, and importantly 25 
PDGFRβ23, akin to the primed PDGFRβ-positive VSMC progenitors reported in models of 26 
hypoxia-induced pulmonary hypertension, which clonally expand in a PDGF-dependent 27 
manner65,66.  This highlights a potential role for PDGF signalling in clonal expansion of 28 
VSMCs, and demonstrates that the study of VSMC clonal expansion in other vascular 29 
conditions20,65,67 may be relevant for further mechanistic dissection in atherosclerosis.    30 
 31 
The small number of VSMCs contributing to lesion formation raises the question of whether 32 
disease-associated proliferation results from activation of specific cells that are primed to 33 
respond to injury (discussed in ref68).  Supporting this idea, transcriptional profiling of 34 
VSMCs from healthy blood vessels revealed significant heterogeneity in expression of genes 35 
associated with vascular disease, suggesting the existence of VSMC subtypes43,56.  36 
Alternatively, clonality may rely on selection of VSMCs with equal plasticity, based on 37 
location (e.g. proximal to breaks in the internal elastic lamina and/or mitogenic signals) or 38 
differential capacity for survival or senescence (see below).  It has also been speculated that 39 
pathways of lateral inhibition may be operating, as is common in development22.  40 
Importantly, these possibilities are not mutually exclusive, and the underlying mechanism is 41 
likely genetic (somatic mutations) and/or epigenetic changes in the expanded VSMCs relative 42 
to non-expanded VSMCs.   43 
 44 
It is well documented that somatic mutations underlie clonal expansion both in malignancy 45 
and in non-malignant tissues as a consequence of aging69.  Indeed, the acquisition of a 46 
particular set of somatic mutations, linked to clonal expansion, in myeloid progenitor cells 47 
has recently been shown to be associated with increased risk of atherosclerosis70.  Therefore, 48 
it is reasonable to suggest that similar mechanisms may underlie clonal expansion of VSMCs 49 
in atherosclerosis.  Indeed, when clonal expansion of VSMCs was first described in plaques it 50 
 6 
was likened to a smooth muscle cell tumour46.  Epigenetic changes may influence clonal 1 
expansion of VSMCs secondary or independently of somatic mutations.  Such changes may 2 
reflect differences in VSMC lineage, environmental stimuli, or stochastic events.    3 
 4 
Whilst lineage tracing has provided the most robust evidence yet for clonality of VSMCs in 5 
plaques, the concept that most plaque VMSCs derive from clonal expansion, attributed to 6 
Benditt and Benditt46, has long been discussed47, particularly in the context of replicative 7 
senescence71. 8 
 9 
 10 
VSMC Senescence  11 
 12 
Senescence is a protective mechanism that induces cell cycle arrest to prevent transmission of 13 
defects to progeny cells, particularly to stop malignant transformation72–74.  Replicative 14 
senescence occurs after repeated cell division, typically after telomere erosion or damage, 15 
while induced senescence arises after oncogene activation, mitochondrial deterioration, DNA 16 
damage, or oxidative stress.  A persistent DNA damage response (DDR) is the most unified 17 
pathway leading to senescence, with sensing by the Ataxia Telangiectasia Mutated (ATM) 18 
protein leading to p53 phosphorylation and upregulation of cell cycle inhibitors72–74.  The 19 
cyclin-dependent kinase inhibitor (cdki) p21 drives initial cell cycle arrest, allowing repair of 20 
moderate DNA damage and re-entry into the cell cycle.  However, prolonged arrest 21 
upregulates the cdki p16Ink4a, leading to dephosphorylation of retinoblastoma protein pRB, 22 
causing permanent cell cycle arrest72–74. 23 
 24 
With every somatic cell division approximately 20bp or more is lost from the telomere ends 25 
of chromosomes.  Thus, repeated cell division leads to critical shortening, telomeric erosion 26 
and loss of the protective Shelterin complex, which results in a persistent DDR that instigates 27 
senescence.  VSMC senescence in vivo is likely driven by multiple pathways including DNA 28 
damage, mitochondrial deterioration, and oxidative stress – all present during atherosclerosis. 29 
Loss of autophagy can also drive VSMC senescence75.  Replicative senescence is highly 30 
relevant in the context of plaque VSMC clonality, as to generate all the VSMC-derived cells 31 
in advanced plaques by clonal expansion would likely cause replicative senescence.  In 32 
keeping with this, the telomeres of VSMCs in human plaques are markedly shortened, which 33 
correlates with disease severity76.   34 
 35 
Most senescent cells develop altered secretory activities known as a senescence-associated 36 
secretory phenotype (SASP)77,78.  Cells with SASPs release proinflammatory cytokines (such 37 
as IL-6, IL-1) and chemokines (such as IL-8, CCL2, CXCL1), growth factors (such as G-38 
CSF, bFGF), and proteases (including MMPs, PAI-1), conferring diverse activities78.  IL-1α 39 
is the key driver of the SASP79,80, with upstream expression controlled in part by ATM/ATR-40 
mediated liberation of GATA4 from p62-directed autophagy81 and/or an mTORC1-dependent 41 
pathway82.  In a physiological setting SASPs act as a molecular beacon that recruits and 42 
instructs immune cells to remove senescent cells (senescent surveillance83) before further 43 
mutation enables senescence bypass and, for example, re-initiation of tumour formation.  44 
However, uncleared senescent cells accumulate during aging and disease (perhaps due to a 45 
dysfunctional immune system or a suppressive milieu), and these generate chronic 46 
inflammation that could worsen outcome and/or drive atherosclerosis84. 47 
 48 
Although VSMC senescence occurs in human plaques, proving the effects of senescent 49 
VSMCs is difficult, and hampered by technical difficulties in mouse models. For example, 50 
 7 
telomeres are approximately 10 times longer in mice than in humans, studying mouse SASPs 1 
in vitro is problematic85, and detecting senescence with the classic markers p16 and 2 
senescence associated β-galactosidase (SAβG) is also notoriously difficult in mice, 3 
particularly when both markers are expressed by macrophages in atherosclerotic plaques.  4 
Two main experimental approaches have been used to study the effect of VSMC senescence 5 
in atherosclerosis; modulation of senescence induction via the DDR, and clearance of 6 
naturally occurring senescent cells with ‘senolytics’.  For example, VSMC-specific 7 
expression of loss-of-function mutant TRF2 (a Shelterin subunit) led to increased DNA 8 
damage and VSMC senescence, with bigger plaques and necrotic cores, while gain-of-9 
function TRF2 produced opposite effects86.  Similarly, VSMCs that lack base excision repair 10 
activity have increased oxidative DNA damage and cell senescence, and promote increased 11 
plaque size87.  In contrast, an intriguing recent study utilised electron microscopy to identify 12 
crystals proposed to be the product of X-Gal cleavage by SAβG84.  This study reported more 13 
than 50% of all plaque cells to be senescent, including VSMCs, macrophages and endothelial 14 
cells84.  Senescent cells appeared within 9 days of fat feeding, and both genetic and 15 
pharmacological elimination of p16 positive cells reduced plaque formation and 16 
progression84. Although it is unclear which cells were senescent and removed by these 17 
treatments, this approach may open a new paradigm for atherosclerosis treatment. 18 
 19 
 20 
VSMCs in different stages of atherosclerosis 21 
 22 
Studies of plaque histology from human autopsy tissues have culminated in a scheme for 23 
classification of plaques that encapsulates the progression of atherosclerosis88,89 and, based 24 
on careful observations of plaque composition from human autopsy and animal models, it is 25 
clear that VSMCs are major contributors to plaque development at all stages (summarised in 26 
FIG. 1).  However, their role and effects of VSMC proliferation or loss may differ according 27 
to the stage of atherogenesis. 28 
 29 
 30 
Pre-atherosclerosis 31 
 32 
Diffuse intimal thickenings (DITs), and intimal xanthomas (i.e. fatty streaks) are considered 33 
pre-atherosclerotic plaques, because they are common from birth90,91 and likely represent 34 
physiological adaptation to blood flow92.  However, the relationship between intimal 35 
xanthomas and atherosclerosis is controversial because, although they localise to 36 
atherosclerosis-prone regions and some intimal xanthomas develop into atherosclerotic 37 
plaques, they are also found elsewhere and sometimes regress93–95.  In contrast, DIT 38 
distribution in the young is similar to that of atherosclerotic plaques in later life90,96 and DITs 39 
are widely considered the most likely precursor to atherosclerotic plaques88.   40 
 41 
Human DITs comprise VSMCs, proteoglycans and elastin, and lack macrophages and 42 
thrombus88,91,92.  VSMCs in DITs exhibit clonality47,91, and are thought to originate from 43 
local medial VSMCs56.  However, the latter is difficult to prove as many techniques for 44 
lineage tracing (e.g. reporter gene expression from a lineage-specific promoter), are limited to 45 
animal models, and most mammals (including mice) do not develop DITs97.  VSMCs in DITs 46 
are heterogeneous, but most exhibit increased synthetic organelles (rough endoplasmic 47 
reticulum, ribosomes and mitochondria) compared to medial VSMCs98, consistent with 48 
switching to a synthetic phenotype, which is supported by decreased expression of contractile 49 
genes99 and increased expression of ECM components100.  VSMCs are thought to be the 50 
 8 
major source of the ECM in DITs, which accounts for much of the increase in thickness of 1 
the intima but, importantly for progression to atherosclerosis, DITs are rich in proteoglycans 2 
that are crucial for retention of apolipoproteins101.  Furthermore, synthetic phenotype VSMCs 3 
metabolise lipid differently to contractile VSMCs, in part through decreased expression of 4 
cholesterol esterase and reduced cholesterol efflux transporter ABCA160,102, resulting in 5 
increased tendency towards foam cell formation103.   6 
  7 
 8 
Early atherosclerosis  9 
 10 
The first stage in atherosclerosis is the formation of pathological intima thickenings (PITs); 11 
the earliest recognised atherosclerotic plaque, which is characterised by the formation of an 12 
extra-cellular lipid pools deep in the intima, underlying abundant VSMCs and ECM88,89.  13 
DITs can, but do not always, progress to PITs (FIG. 2)104.  Progression is promoted through a 14 
complex interplay between retention and oxidation of lipid, induction of inflammation, and 15 
VSMC proliferation, phenotype switching, and death.   16 
 17 
The lipid pools(which is distinct from the necrotic pool of more advanced plaques) comprises 18 
lipids (including free cholesterol) amidst a proteoglycan (notably biglycan, versican and 19 
perlecan) and glycosaminoglycan (GAG, including hyaluronan) -rich ECM.  As the 20 
predominant cell-type present in DITs, intimal VSMCs are regarded as the most important 21 
source of the ECM, and this is supported by analysis of the secretome of VSMCs in vitro105–22 
109.  The ECM has a central role in initiation of atherosclerosis, primarily through the 23 
interaction between the negatively charged side chains of proteoglycans (particularly 24 
chondroitin sulphate of biglycan and versican and heparin sulphate of perlecan110) with 25 
positively charged apolipoproteins (especially apolipoprotein B) , which leads to the retention 26 
of plasma-derived lipoproteins101,111 - as described in the ‘response to retention 27 
hypothesis’112,113.  Transgenic mice over-expressing biglycan in VSMCs show more lipid 28 
retention and increased atherosclerosis than wild-type litter-mates114.  Once retained in the 29 
intima, lipoproteins undergo modifications, including oxidation to OxLDL, which precedes 30 
the recruitment of macrophages115 and initiates the inflammatory response characteristic of 31 
atherosclerosis112.  Further evidence for this series of events was provided by a recent study 32 
comparing DITs to PITs, in which extra-cellular lipid was found deep in the plaque, 33 
colocalising with αSMA-positive cells, ApoB, biglycan and versican, but not the more 34 
superficial (closer to the lumen) CD68 positive cells (likely macrophages)116.  35 
 36 
Progression to PITs is accompanied by loss of αSMA, which is likely due to a combination 37 
of phenotypic switching of VSMCs11,18,23 and loss of VSMCs through cell death117,118.  For 38 
example, uptake of OxLDL and formation of VSMC-derived foam cells has been linked to 39 
induction of VSMC death by apoptosis118, and free cholesterol in the lipid pool may be 40 
derived from dead VSMC119.  The micro-calcification (speckles of 0.5-15µm) sometimes 41 
observed within the lipid pool of PITs, typically close to the border with the media, may also 42 
be a consequence of VSMC apoptosis51. 43 
 44 
Macrophages may be absent from early PITs89, but are a defining characteristic of late stage 45 
PITs and crucial to the progression of PITs to fibroatheromas.  Lineage tracing studies have 46 
shown the macrophage marker-positive cells of early lesions in mice (which resemble intimal 47 
xanthomas) are mostly derived from recruited circulating monocytes23,120, and may also 48 
involve local resident macrophages121,122.  However, co-expression of αSMA and CD68 in 49 
human plaques indicate that VSMCs also likely contribute significantly to the macrophage 50 
 9 
marker-positive cells in early plaques5,61.  Monocytes are recruited to PITs through the 1 
expression of adhesion molecules (including selectins, ICAM1, VCAM1, CD31123) and 2 
chemo-attractants, including chemokines (such as CCL5, CXCL1 and CCL2120,124 , which are 3 
secreted by VSMCs and ECs stimulated with inflammatory cytokines or OxLDL, in vitro125) 4 
and modified lipids (such as OxLDL126).  Studies in animal models have collectively revealed 5 
an essential requirement for macrophages in the progression of atherosclerosis120,122,127,128, 6 
which is likely to involve effects on VSMC migration, proliferation (through production of 7 
factors such as PDGF129) and phenotype switching130. 8 
 9 
 10 
Late atherosclerosis  11 
 12 
PITs can progress to fibroatheromas (FIG. 3), characterised by the presence of a fibrous cap 13 
and a necrotic core, the origins of which are the extra-cellular lipid pool and insufficient 14 
efferocytosis (of dead VSMCs and macrophages)131–133.  This phase of atherosclerosis (late 15 
PIT/early fibroatheroma) is dependent on extensive accumulation of macrophages on the 16 
luminal side of the lipid pool, where they phagocytose deposited lipids to become foam cells.  17 
In the absence of resolution, the ensuing inflammatory reaction is self-perpetuating; 18 
macrophages and VSMCs become foam cells, which die (mostly by apoptosis but potentially 19 
through other mechanisms, Box 4).  Since the plaque milieu suppresses efferocytosis133–136, 20 
uncleared apoptotic cells subsequently undergo secondary necrosis with release of further 21 
inflammatory material, such as damage-associated molecular patterns (DAMPs)137.  The 22 
accompanying healing response involves the formation of the fibrous cap, which, at least in 23 
the early stages, is a highly cellular region, rich in VSMC-derived αSMA-positive cells22,40–24 
42, amongst an altered ECM  that has decreased proteoglycan expression and an increase in 25 
the proportion of collagens (mostly type I and III).   26 
 27 
In mice, the fibrous cap VSMCs are derived from medial VSMCs22,138 that have undergone 28 
migration and proliferation in response to cytokines and growth factors, such as PDGF, 29 
derived from macrophages and activated ECs23,129,139.  This initial stage of VSMC 30 
recruitment is, at least in part, Oct4 dependent21.  In humans, both pre-existing intimal and 31 
medial VSMCs may contribute to plaque VSMCs48.  Definitive proof that VSMCs are 32 
responsible for the production of the fibrous cap ECM is lacking.  However, this hypothesis 33 
is consistent with co-localization of collagen synthesis to VSMCs in the fibrous cap140, 34 
correlation of fibrous cap thickness with VSMC phenotype in mice11,21,141, and the correlation 35 
of fibrous cap stability with VSMC cell number in humans142.  In addition, a recent study of 36 
VSMC-specific deletion of Col15a resulted in a greater than 70% reduction in Col15a, 37 
supporting VSMCs as the major source of this collagen143.  Further evidence that VSMCs are 38 
the major source of collagens comes from studies in vitro, including proteomic analysis of the 39 
secretome of lipid-loaded VSMCs109 and induction of collagen synthesis by VSMCs in 40 
culture by TGF-β, PDGF, IL-1, AngII, cholesterol, homocysteine and mechanical 41 
stretch144,145. 42 
 43 
VSMCs in the later stages of atherosclerosis have previously been thought to be entirely 44 
beneficial, for example by stabilising the plaque through elaborating the fibrous cap.  45 
However, lipid loading of VSMCs and altered interactions with the ECM lead to altered 46 
VSMC phenotype, and increased macrophage markers59.  Indeed, VSMCs contribute between 47 
30-70% of the macrophage marker-positive cells11,20 and similarly to foam cells146 in mouse 48 
plaques, and around 30-40% of CD68 positive cells and 50% of foam cells in humans11,60.  49 
VSMC-specific deletion of the transcription factor KLF4 reduces VSMC switching to 50 
 10 
macrophage marker-positive cells, and results in a marked increase in the thickness and 1 
αSMA-positive cell content of the fibrous cap11.  Although these studies have shown that 2 
VSMCs can express macrophage markers, in vitro studies of the transcriptomes of VSMCs 3 
and macrophage-derived foam cells indicate they are functionally distinct, and that VSMC-4 
derived foam cells exhibit reduced phagocytic and efferocytic responses59.  VSMCs have 5 
long been known to contribute to the inflammatory milieu of the plaque through recruitment 6 
of macrophages; however, these studies strongly suggest that VSMC-derived macrophage-7 
like cells also directly affect plaque progression.  8 
 9 
In early fibro-atheromas, calcification is observed as large granules in the necrotic core and 10 
surrounding ECM, resulting from a number of interrelated processes, including macrophage 11 
and VSMC-derived calcifying micro-vesicles147–149, release of apoptotic bodies150 or the 12 
activity of osteochondrogenic cells151.  As the fibro-atheroma develops, micro-calcifications 13 
can coalesce into larger speckles and fragments that can form sheets or plates149 visible by 14 
tomography.  Fragmentation of these sheets and fibrin encapsulation can lead to the 15 
formation of calcium nodules, which protrude into the vessel lumen and precipitate 16 
thrombosis88.  The extent of plaque calcification varies according to the vascular bed, and a 17 
recent study linked this to the different propensities of the local, developmentally distinct, 18 
VSMCs to undergo calcification152,153.  VSMCs have long been linked to calcification150,154  19 
and osteochondrogenic conversion in vitro is enhanced by plaque-like environmental cues, 20 
including phenotypic conversion155, apoptotic bodies150, oxLDL156, and inflammatory 21 
cytokines such as TNFα157, IL-1158 and IL-18159.  Furthermore, specific genetic modulation 22 
of VSMC osteochondrogenesis in vivo leads to altered calcification in models of 23 
atherosclerosis160–162.  Most convincingly, however, recent studies have established that most 24 
of the osteochondreogenic precursors (Runx2/Cbfa1+ cells) and chondrocyte-like (type II 25 
collagen+) cells of murine plaques are again VSMC-derived138.   26 
 27 
 28 
Clinical sequalae 29 
 30 
The major clinical sequelae of atherosclerosis are dependent on the anatomical site of the 31 
vascular bed involved (angina and myocardial infarction in coronary arteries; stroke in 32 
carotid arteries) and typically manifest as a result of thrombosis.  The primary cause 33 
(accounting for around 60% to 70% of cases) of thrombosis is plaque rupture163 and the 34 
remaining cases are predominantly the result of plaque erosion (the latter being much more 35 
frequent in young individuals, particularly women) (FIG. 4).  A minority (typically around 36 
5%) are due to thrombosis forming on calcified nodules.  However, thrombosis and clinical 37 
sequalae are not an inevitable consequence of atherosclerosis; analysis of autopsies has 38 
shown that plaques often show evidence of silent (non-occlusive) thrombi which have 39 
undergone repair and healing.  Furthermore, the widespread uptake of clinical interventions, 40 
including lipid-lowering, are changing the clinical presentation of atherosclerosis in 41 
association with changes in the characteristics of the ‘vulnerable plaque’164. 42 
 43 
As the fibroatheroma develops, so does the necrotic core; the free cholesterol content and 44 
calcification increases, and there is breakdown and remodelling of the fibrous cap ECM.  The 45 
latter is thought to be principally due to the actions of proteases (in particular 46 
metalloproteinases165), but also by sulphatases and exoglycosidases that are predominantly 47 
released by macrophages166, but may also come from VSMCs167.  Concomitantly, VSMCs 48 
are depleted through cell death, and so the cap diminishes, whilst the growing necrotic core 49 
extends outwards, leading to thinning of the fibrous cap168,169.  Thin-cap fibroatheromas 50 
 11 
(TCFA) are defined by a fibrous cap of less than 65µm, and are also known as ‘vulnerable 1 
plaques’ because studies have shown that these plaques are highly susceptible to rupture.  2 
The underlying mechanisms are ill-defined, but proteolytic activity166,167, mechanical stress170 3 
and micro-calcification of the fibrous cap149,171 have all been linked to plaque rupture.   4 
 5 
Plaque rupture is inversely correlated with VSMC number142, which is determined by 6 
proliferation, migration and death of VSMCs.  Advanced human lesions show little VSMC 7 
proliferation172,173, but VSMC death, through apoptosis and necrosis (Box 4), is increased 8 
compared to normal vessels174–176, and in unstable versus stable plaques177.  Indeed, VSMC 9 
apoptosis has been postulated to be key to plaque instability178.  Seminal work showed plaque 10 
VSMCs to spontaneously undergo apoptosis in vitro, with IGF-1 and PDGF acting as 11 
survival factors179, and plaque VSMCs expressing less IGF-1R180.  Similarly, cell to cell 12 
contact via N-cadherin promotes survival181.  Conversely, numerous factors that induce 13 
VSMC apoptosis have been described, including cell-directed killing (by macrophages, T 14 
lymphocytes and mast cells), ROS, DNA damage, anoikis and cholesterol.  Studies of VSMC 15 
apoptosis in vivo have utilised mice that have either alterations to apoptotic pathways or 16 
systems to induce apoptosis.  Early work with adenoviral p53 expression in plaques led to 17 
VSMC apoptosis and cap thinning182.  Similarly, VSMC-specific diphtheria toxin (DT)-18 
induced apoptosis revealed short term VSMC apoptosis within established plaques to have no 19 
effect on plaque size, but to result in vulnerable plaques with small fibrous caps and a paucity 20 
of VSMCs and structural matrix178 – a finding subsequently corroborated many times in 21 
studies that have promoted or inhibited VSMC death,167,181,183–187.  Strikingly, DT induction 22 
of VSMC apoptosis alongside high fat feeding during atherogenesis resulted in larger 23 
plaques51, showing that the consequences of VSMC death are more than cell loss alone, and 24 
in fact actively drives plaque growth - another well replicated finding167,185,187,188.  A key 25 
controller of VSMC apoptosis in vivo appears to be the survival kinase Akt1183,186,187; 26 
conditional ablation of Akt1 during atherogenesis induces VSMC apoptosis and larger 27 
plaques, and Akt1 ablation in established plaques leads to a reduced fibrous cap.  The 28 
contribution of VSMC death to plaque stability is complex and extends beyond direct cell 29 
loss; with further consequences on the local milieu (such as initiating calcification150), and 30 
wider effects in activating the immune system.  The plaque environment is known to inhibit 31 
phagocytosis133–136, and defective efferocytosis of apoptotic cells leading to secondary 32 
necrosis and leakage of intracellular contents has been proposed to exacerbate the 33 
inflammatory milieu131,132,137.  Indeed, necrotic VSMCs potently drive inflammation via IL-34 
1α due to a lack of IL-1R2 that normally binds and inhibits IL-1α133,189.  Thus, a consensus 35 
appears whereby functional VSMCs are essential to maintain the fibrous cap and thus plaque 36 
stability, but death of VSMCs is a potent driver of atherogenesis.   37 
 38 
A recent study of the VSMC transcriptome in symptomatic versus asymptomatic carotid 39 
plaques has also highlighted the importance of VSMC senescence190.  Unstable mature 40 
plaques show low VSMC proliferation and clear evidence of VSMC senescence191.  41 
Senescent VSMCs were originally thought to promote plaque instability through inaction - 42 
i.e. a lack of VSMC proliferation and matrix production leads to weakening of the fibrous 43 
cap.  However, senescent VSMCs establish a robust IL-1α-driven SASP containing multiple 44 
inflammatory cytokines, chemokines, MMPs and osteogenic factors80,192.  Thus, the VSMC 45 
SASP can recruit mononuclear cells, induce endothelial cell adhesion receptor expression and 46 
activate adjacent normal VSMCs80, effectively amplifying the effect of a small number of 47 
senescent VSMCs.  Senescent VSMCs also produce less collagen and release active 48 
MMP980, while BMP2 and osteoprotegerin within the SASP drive calcification192.  Thus, 49 
 12 
senescent VSMCs can have a negative impact on plaques through both loss of normal 1 
function and a direct effect on the local plaque milieu.  2 
 3 
An alternative route to thrombosis and clinical sequalae is through plaque erosion.  Erosion 4 
refers to the formation of a thrombus in the absence of rupture at sites of endothelial 5 
denudation or disruption.  The underlying plaque may be an intimal thickening or 6 
fibroatheroma88,169, but VSMCs are often abundant, amidst a proteoglycan-rich ECM, 7 
enriched in type III collagen, versican and hyaluronan193.  Recent studies have identified an 8 
important role for hyaluronan, which activates TLR2 signalling upon degradation 194 and this 9 
combined with altered shear stress, leads to endothelial cell activation and apoptosis195, 10 
neutrophil recruitment and thrombosis194.  Thus VSMCs are implicated in the events leading 11 
to plaque erosion, in particular as the major source of hyaluronan196.  12 
 13 
 14 
Future perspectives 15 
 16 
Difficulties in extrapolating studies from mice to man  17 
 18 
Reconciling the results of studies of animal models with those of human atherosclerosis can 19 
be challenging, as there are some important differences in how the disease progresses in 20 
humans and animal models.  This is exemplified in the case of DITs, which are absent in 21 
most animal models.  Another fundamental difference is that fibroatheromas rarely progress 22 
to rupture in animal models, exemplified by the recently reported effects of a neutralising IL-23 
1β antibody, which were deleterious on the fibrous cap in mice141, but beneficial in reducing 24 
cardiovascular events in the CANTOS trial in humans197.  Nonetheless, animal models have 25 
been instructive in delineating important pathways and basic principles that might underlie 26 
plaque development in humans.  This is particularly true of the lineage tracing studies in 27 
mouse models of atherosclerosis, which have unambiguously established the importance of 28 
clonality and phenotype switching of VSMCs.  Combinatorial genetic depletion models will 29 
likely be instrumental in assessing whether biasing the phenotype of VSMC-derived cells 30 
could be a potential treatment avenue.  Recently developed techniques, including mass 31 
cytometry (CyToF) and single-cell omics (genomics, transcriptomics and epigenomics), hold 32 
great promise for high resolution, spatio-temporal analysis of plaque cells in situ, and are 33 
likely to provide the conclusive human counterpart and mechanistic data for the 34 
aforementioned studies.  35 
 36 
 37 
 38 
VSMCs and genetics of atherosclerosis 39 
 40 
Over 150 CAD loci have been identified from GWAS and other genetic association 41 
studies198, many of which are associated with disease independently of other known risk 42 
factors.  Thus, elucidation of the underlying molecular mechanisms may reveal novel 43 
pathways and hence targets for therapeutic intervention.  However, identification of causal 44 
variants is usually far from trivial; CAD loci are often located in non-coding regions, where 45 
the causal variant is predicted to effect regulation of gene expression, which may operate 46 
over large distances and be cell-type or context specific.  Studies are ongoing to identify and 47 
functionally characterise the causal variants responsible for each of the CAD loci, and in vitro 48 
studies of VSMCs are proving an invaluable resource in this quest.  Integration of 49 
transcriptomic and epigenomic maps from VSMCs (and other plaque cells) with those of the 50 
 13 
genetic architecture of CAD can be very informative for prioritising variants (and potential 1 
pathways) for functional characterisation199,200.  Unsurprisingly, given the key role of VSMCs 2 
in atherosclerosis, a number of loci have been predicted to modulate disease risk through 3 
mechanisms specific to VSMCs200.  Thus, studies in cultured VSMCs, and more recently 4 
VSMCs derived from stem cells49,201, are likely to be instrumental in the functional 5 
characterisation of CAD variants.  Recent pioneering examples of such studies include the 6 
characterisation of the SMAD3 and TCF21 loci202.    7 
 8 
 9 
Conclusion  10 
 11 
The role of VSMCs in atherosclerosis extends far beyond that perceived for decades.  12 
VSMCs and VSMC-derived cells comprise a (if not the) major source of plaque cells, and 13 
contribute to numerous plaque cell phenotypes, including macrophage-like and foam cells, in 14 
addition to cells responsible for producing the atherogenic and or athero-protective ECM 15 
throughout the disease.  Thus, VSMCs are implicated mechanistically at all stages of 16 
atherosclerosis, and recent studies have established the extent and importance of VSMC 17 
clonality and phenotype switching in plaque progression.  These concepts have been around 18 
for decades, but it is only very recently that technologies for genetic engineering and imaging 19 
have converged with a deeper understanding of developmental processes to generate 20 
conclusive data in animal models.  The era of single cell omics promises to deliver the 21 
evidence as to if and how these processes contribute to the disease in humans.  It is clear that 22 
a better understanding of the biology of VSMCs is required if we are to fulfil aspirations of 23 
selectively targeting ‘culprit’ cells or manipulating cell phenotype to enhance clinical benefit 24 
and/or avert processes that are detrimental in disease. 25 
 26 
 27 
Key points: 28 
- VSMCs and VSMC-derived cells are a major source of plaque cells and ECM at all stages 29 
of atherosclerosis 30 
- VSMCs contribute to many different plaque cell phenotypes, including ECM-producing 31 
cells of the fibrous cap, macrophage-like cells, foam cells, mesenchymal stem cell-like and 32 
osteochondrogenic cells  33 
- Recently progress has been made regarding the source of plaque VSMCs and VSMC-34 
derived cells, which highlights the importance of developmental origin, clonal expansion and 35 
phenotype switching of VSMCs in atherosclerosis 36 
 37 
  38 
 14 
Box 1: Historical perspective on VSMCs in atherosclerosis  1 
 2 
The development of antibodies for ‘VSMC-specific’ function-associated markers, such as 3 
smooth muscle alpha actin (αSMA)6–9, greatly facilitated immuno-histological studies of 4 
VSMCs in plaques of animal models203,204 and humans98,103.  These studies, alongside in vitro 5 
culture models55 and models of arterial injury, such as balloon angioplasty, revealed that 6 
VSMCs are capable of great phenotypic plasticity, and undergo ‘phenotypic switching’ from 7 
contractile to proliferative synthetic phenotypes205–207.  Phenotype switching and proliferation 8 
of VSMCs in response to arterial injury and lipid infiltration were considered the main 9 
pathological processes underlying plaque development207.   10 
 11 
Studies in the 1990s characterised the role of VSMC proliferation, migration, apoptosis, and 12 
phenotype switching in atherogenesis208,  and revealed that VSMCs can give rise to foam 13 
cells4,5,102 and osteochondrogenic cells154.  However, detailed post-mortem analyses of culprit 14 
plaques in sudden cardiac death established that the integrity of the fibrous cap, comprising 15 
mostly αSMA-positive cells and associated extracellular matrix (ECM), is critical to stabilise 16 
and protect plaques from rupture, a major cause of the clinical sequalae of 17 
atherosclerosis142,163,168.  These studies also highlighted the role of immune cells, particularly 18 
macrophages, and inflammation as the main driver of plaque development169.  Thus, the 19 
prevailing model has been that VSMCs contribute to the cellularity and inflammation of the 20 
developing plaque, but have a predominantly beneficial role in its stabilisation though 21 
elaborating the fibrous cap209. 22 
 23 
In the last decade, studies applying fate mapping and lineage tracing techniques have 24 
revealed the limitations of relying on ‘VSMC-specific’ function-associated markers to infer 25 
VSMC identity, and exposed the extent to which this can lead to false negative and false 26 
positive identification of VSMCs, as well as oversimplification of VSMC heterogeneity and 27 
functions in plaques11,17,18.  28 
 29 
Text boxes (for timeline): 30 
 31 
pre 1900s histology on morbid specimens, including by Virchow (1856) who proposed 32 
atherosclerosis to result from inflammation and proliferation as a consequence of arterial 33 
injury by mechanical forces 34 
 35 
Marchand coins ‘atherosclerosis’ 36 
 37 
Ignatowsky describes relationship between protein/lipid-rich diet and experimental 38 
atherosclerosis, these studies were extended by Anichkov in 1913, who  discovered the 39 
importance of cholesterol 40 
 41 
Foam cells observed in human and experimental atherosclerosis studies by light 42 
microscopy210,211 43 
 44 
Pease describes VSMC as the only cell-type in the healthy media by electron microscopy2.  45 
Studies of experimental and human atherosclerosis  quickly followed, revealing VSMC 46 
derived cells as prominent cell type in plaques3–5 47 
 48 
 15 
Wissler proposes VSMC are the primary cell type involved in atherosclerosis, assimilating 1 
many studies (including Wolinsky & Glagov212) that VSMC are the contractile and ECM-2 
producing cells of the media and, furthermore, contribute to plaque foam cells62 3 
 4 
Ross further develops ‘response to injury hypothesis’, emphasizing the role of PDGF 5 
mediated VSMC proliferation207 (firstly due to EC injury and platelet activation213 and later 6 
updated to incorporate a role for macrophage derived PDGF129)    7 
 8 
Benditt & Benditt propose plaque VSMC arise from clonal expansion46 9 
 10 
Chamley-Campbell et al identify phenotype switching in cultured VSMCs55 11 
 12 
‘vulnerable plaque’ concept developed; studies of culprit plaques in cardiac deaths identify 13 
fibrous cap integrity essential to plaque stability163,168,214 14 
 15 
ApoE and LDLR mouse models of atherosclerosis developed203,204 16 
 17 
‘response to retention hypothesis’ proposed113 and supported by identification of the central 18 
role of ApoB containing lipoproteins101 19 
 20 
first lineage tracing studies11,17,18 which collectively revealed VSMC contribution much more 21 
substantial than previously thought, giving rise to macrophage marker positive cells, foam 22 
cells, osteochondrogenic and mesenchymal stem cell like cells 23 
 24 
multi-colour lineage tracing studies demonstrate multiple plaque phenotypes are derived from 25 
common ancestor – revealing the true extent of VSMC clonality in plaques20,22 26 
 27 
CANTOS trial establishes causal role for inflammation in pathogenesis of atherosclerosis197 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
  39 
 16 
Box 2: Embryonic origins of VSMCs and sources of VSMC progenitors in adults   1 
 2 
During embryonic development, medial VSMCs (and in some instances pericytes215) arise 3 
from local progenitor cells, of which there are multiples distinct lineages distributed across 4 
the arterial tree.  In mice, more than eight distinct progenitor populations have been 5 
identified44,216,217.  The aortic root and outer medial layers of the ascending aorta derive from 6 
the secondary heart field26,28; the inner medial layer of the ascending aorta, aortic arch, ductus 7 
arteriosus, innominate and right subclavian arteries, right and left common carotid arteries 8 
derive from the neural crest25; the descending aorta derives from paraxial (somatic) 9 
mesoderm218; and the coronary arteries are derived from pro-epicardium, which derives from 10 
lateral plate mesoderm219. 11 
 12 
Potential VSMC progenitor populations have also been identified in the media in the adult 13 
mouse, including VSMC-derived cells expressing Sca1 and other mesenchymal stem cell 14 
markers11,43. These cells may be an intermediate population derived from phenotypic 15 
switching, which can give rise to different VSMC-derived cell phenotypes43.  Other potential 16 
progenitor cells include a population of adventitial cells located close to the medial boundary 17 
that express mesenchymal stem cell markers (e.g. Sca1) and are sonic hedgehog signalling-18 
responsive (Gli1 positive)27,220–222, and pericytes223,224, which are VSMC-like cells of the 19 
microvasculature.  20 
 21 
Importantly, studies have shown that progenitors with distinct origins may achieve a common 22 
VSMC fate with respect to expression of ‘VSMC-specific’ function-associated markers 23 
(through pathways discussed in Box 3), but are nonetheless distinct with respect to other 24 
functional characteristics, such as responses to growth factors.   25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
  43 
 17 
Box 3: Molecular mechanisms underlying VSMC plasticity 1 
 2 
Transcription factors:  3 
 4 
Myocardin (MYOCD) family proteins drive expression of contractile genes57. 5 
MYOCD is a co-factor for serum response factor (SRF), which binds CArG-box 6 
elements within contractile gene promoters.  Most environmental cues and signalling 7 
pathways affecting VSMC function impact the expression and/or activity of 8 
MYOCD225,226  9 
 10 
KLF4 represses contractile gene expression through several mechanisms, including 11 
binding to G/C repressor elements and inhibiting SRF binding to CArG-boxes.  KLF4 12 
inhibits proliferation; VSMC specific deletion of CHOP leads to decreased VSMC 13 
proliferation through increased expression of KLF4227.  Importantly, VSMC 14 
phenotype switching is KLF4 dependent.  KLF4 is required for induction of 15 
progenitor cells prior to clonal expansion of pulmonary VSMCs in hypoxia65,66 and 16 
VSMC-specific deletion of KLF4 in ApoE-/- animals results in reduced numbers of 17 
VSMC-derived macrophage and mesenchymal stem cell marker positive plaque 18 
cells11.   19 
 20 
 21 
Extracellular stimuli: the contractile phenotype is promoted by TGF-β, whereas PDGF 22 
induces KLF4 expression, VSMC proliferation and phenotypic switching.  Other growth 23 
factors including WNT signalling also promote proliferation and migration of VSMCs.  Pro-24 
inflammatory cytokines (e.g. IL-1 and TNF-α) perturb VSMC phenotype via NF-κB and AP-25 
1 mediated gene regulation, including MYOCD downregulation.  Cholesterol-induced 26 
activation of macrophage-associated gene expression in VSMC occurs via microRNA-27 
143/145, involves MYOCD and inflammatory signalling and is affected by KLF459,228. 28 
 29 
Cell interactions: ECM proteins and heparin affect VSMC phenotype229.  Notably, deletion 30 
of integrin β3 results in larger lesions and affects VSMC clonality in atherosclerosis23. 31 
Differences in how cells communicate with the environment may also explain the 32 
documented effect of stretch and shear stress on VSMC phenotype230.  33 
 34 
Epigenetic regulation: the reversibility of VSMC phenotypic switching indicates a cellular 35 
memory of the contractile state.  Indeed, contractile genes remain marked by H3K4me2 36 
(generally associated with actively transcribed genes) after phenotypic switching18 and  37 
manipulation of DNA methylation and histone modifying enzymes directly affect VSMC 38 
behaviour in murine models of vascular injury and atherosclerosis231–233, whilst levels of 39 
epigenetic markers are altered in human plaques234.  Non-coding RNAs also control VSMC 40 
plasticity235,236 evidenced by the effect of specific miRNAs and long non-coding RNAs on 41 
VSMC biology and function237,238. 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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Box 4: Mechanisms of cell death 1 
 2 
 3 
Apoptosis: the commonest form of programmed cell death (PCD) utilised throughout 4 
development and day-to-day physiology.  Executed by apoptotic caspases (e.g. 3, 7), with 5 
main initiation pathways controlled via the mitochondria (via Bcl-2 family members) or 6 
external death receptors (e.g. Fas, TNFR).  Apoptotic cells must be phagocytosed, or 7 
secondary necrosis with leakage of inflammatory contents (including DAMPs) will occur.  8 
All major cell types within the plaque are witnessed to undergo apoptosis. 9 
  10 
Autophagic cell death: a mechanism for the organised degradation and recycling of 11 
intracellular components within double membraned autophagosomes that fuse with 12 
lysosomes.  Can be a response to stress that enables the cell to survive, but is also witnessed 13 
as PCD.  VSMC specific deficiency in autophagy leads to increased VSMC death and 14 
enhanced features of vulnerable plaques188.   15 
  16 
Necrosis: An un-programmed form of cell death characterized by catastrophic loss of plasma 17 
membrane integrity and leakage of cell contents.  Uncleared dying cells default to secondary 18 
necrosis.  Difficult to prove in vivo, but ultrastructural evidence suggests necrotic plaque 19 
macrophages and VSMCs occur. 20 
  21 
Necroptosis: A programmed form of necrosis allowing cell suicide when apoptosis is 22 
blocked (e.g. viral caspase inhibitors).  Utilises RIPK1/3 to form the ripoptosome which 23 
activates MLKL that destroys the plasma membrane.  Increased RIP3 and MLKL reported in 24 
human plaques, but difficult to specifically detect necroptosis. 25 
  26 
Pyroptosis: Inflammatory form of cell death that occurs in concert with inflammasome 27 
activation and IL-1 production, often in response to intracellular infection.  Leads to 28 
activation of inflammatory caspases (e.g. 1, 4, 5, 11) that activate IL-1 and/or the pore-29 
forming protein GSDMD, and subsequent membrane permeabilisation. Likely happens in 30 
plaques after cholesterol crystal activation of macrophage NLRP3 inflammasomes.  31 
  32 
Paraptosis: caspase-independent cell death leading to cytoplasmic vacuolation and eventual 33 
osmotic lysis. Not currently described in atherosclerotic plaques. 34 
 35 
 36 
 37 
 38 
 39 
 40 
 19 
Table 1: Lineage tracing studies in atherosclerosis 1 
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Figure legends  2 
 3 
Figure 1: Overview of the role of vascular smooth muscle cells (VSMCs) in 4 
atherosclerosis 5 
VSMCs are a major source of plaque cells and extra-cellular matrix (ECM) at all stages of 6 
atherosclerosis and contribute to numerous processes throughout the disease.  7 
 8 
Figure 2: VSMCs in early atherosclerosis 9 
Summary of the role of VSMCs in early atherosclerosis (progression from diffuse intimal 10 
thickening to pathological intimal thickening).  VSMCs are the predominant cell type and 11 
source of atherogenic, lipid (particularly LDL)-retentive extra-cellular matrix in early 12 
atherosclerosis.  Retained LDL is susceptible to modifications, such as oxidation (to 13 
OxLDL).  Uptake of OxLDL by VSMCs leads to foam cell formation and death by apoptosis.  14 
Activated VSMC secrete chemokines and contribute to recruitment of monocytes, which 15 
differentiate to macrophages.  Progression to PITs is typically associated with decreased 16 
VSMC marker positive cell content (such as smooth muscle alpha actin positive cells, 17 
αSMA+) and increased macrophage marker positive cells (such as CD68+ cells), likely 18 
reflecting a combination of VSMC death and VSMC phenotype switching to macrophage 19 
like cells (as a consequence of decreased MYOCD and increased KLF4).   20 
 21 
Abbreviations: ABCA1, ATP-binding cassette transporter 1 ApoB, apolipoprotein B; CCL2, CC motif 22 
chemokine 2 (also known as MCP-1); CCL5, CC motif chemokine 5 (also known as RANTES); CXCL1, CXC 23 
motif chemokine 1 (also known as GROα); DIT, diffuse intimal thickening, ECM, extra-cellular matrix; ECs, 24 
endothelial cells; ICAM1, intercellular adhesion molecule 1; KLF4, Krüppel like factor 4; LDL, low density 25 
lipoprotein; MYOCD, myocardin; PIT, pathological intimal thickening; SR, scavenger receptor; VCAM1, 26 
vascular cell adhesion molecule 1; VSMCs, vascular smooth muscle cells. 27 
 28 
 29 
 30 
Figure 3: VSMCs in late atherosclerosis 31 
Summary of the role of VSMCs in late atherosclerosis (progression from pathological intimal 32 
thickening to fibroatheroma).  This phase of atherosclerosis is characterised by the 33 
elaboration of the fibrous cap by VSMCs, and the necrotic core, which is the consequence of 34 
defective efferocytosis of apoptotic cells (mostly VSMCs and macrophages).  Through 35 
phenotype switching, VSMCs contribute to many different plaque cell phenotypes, including 36 
the extra-cellular matrix -producing cells of the fibrous cap, macrophage-like cells, foam 37 
cells, mesenchymal stem cell-like and osteochondrogenic cells.  VSMC also contribute to 38 
calcification through a number of mechanisms, including apoptosis and osteochondrogenic 39 
conversion. 40 
 41 
Abbreviations: αSMA, smooth muscle alpha actin; DAMPs, damage associated molecular patterns; ECM, extra-42 
cellular matrix; IL-1α, interleukin-1 alpha; KLF4, Krüppel like factor 4; LDL, low density lipoprotein; MSC-43 
like, mesenchymal stem cell-like; MYOCD, myocardin; PDGF, platelet derived growth factor; PIT, 44 
pathological intimal thickening; VSMCs, vascular smooth muscle cells. 45 
 46 
 47 
Figure 4: VSMCs in clinical sequalae of atherosclerosis 48 
Summary of the role of VSMCs in plaque rupture and plaque erosion, the two major 49 
processes underlying thrombosis and hence the clinical sequalae of atherosclerosis. 50 
 51 
 34 
Abbreviations: ECM, extra-cellular matrix; EC, endothelial cell; IL-, interleukin-; MMPs, matrix 1 
metalloproteinases; SASP, senescence associated secretory phenotype; TLR, Toll like receptor; VSMCs, 2 
vascular smooth muscle cells. 3 
 4 
Table 1:  Lineage tracing studies in atherosclerosis 5 
 6 
 7 
Glossary 8 
 9 
Clonal expansion – proliferation of a single or limited number of ancestral cells 10 
Foam cell – lipid laden cells with a foamy appearance  11 
Lineage tracing – technique of following the fate of labelled cells to enable identification of 12 
progeny cells 13 
Mesenchymal stem cells – multipotent stromal cells 14 
Osteochondrogenic cells – cells capable of generating osteocytes and or chondrocytes  15 
Phenotype switching – process by which VSMCs alter phenotype, often infered through 16 
decreased expression of VSMC-specific contractile genes and or increased expression of 17 
markers typical of synthetic VSMCs or other cell-types 18 
Response to retention hypothesis – hypothesis that sub-endothelial retention of lipid, in the 19 
form of lipoproteins, is the initial step in atherogenesis 20 
Shelterin complex – multi-protein complex (including TRF2) which binds the repetitive 21 
sequences of telomeric DNA, protecting against DNA damage  22 
Vulnerable plaque – plaque with a phenotype associated with increased risk of rupture, also 23 
known as thin-cap fibroatheromas, defined by a thin fibrous cap (of less than 65µm) and 24 
large necrotic core 25 
 26 
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